Wells Fargo & Company Atara Biotherapeutics, Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 39,988 shares of ATRA stock, worth $308,307. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,988

Previous 35,365 13.07%

Holding current value

$308,307

Previous $18,000 50.0%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.44 - $1.22 $2,034 - $5,640	4,623 Added 13.07%	39,988 $27,000
Q4 2023 Feb 09, 2024	SELL	$0.23 - $1.74 $201 - $1,527	-878 Reduced 2.42%	35,365 $18,000
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.31 $18,738 - $30,699	-13,290 Reduced 26.83%	36,243 $53,000
Q2 2023 Aug 15, 2023	SELL	$1.5 - $3.04 $111,153 - $225,270	-74,102 Reduced 59.94%	49,533 $79,000
Q1 2023 May 12, 2023	BUY	$2.8 - $5.46 $310,478 - $605,432	110,885 Added 869.69%	123,635 $358,000

Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $16,504 - $29,997	-5,791 Reduced 31.23%	12,750 $41,000
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $36,921 - $113,097	-12,955 Reduced 41.13%	18,541 $70,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $41,206 - $86,454	8,786 Added 38.69%	31,496 $246,000
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $257,048 - $514,401	-30,456 Reduced 57.28%	22,710 $211,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $49,494 - $66,969	-3,367 Reduced 5.96%	53,166 $837,000
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $1.2 Million - $1.8 Million	-100,411 Reduced 63.98%	56,533 $1.01 Million
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $268,936 - $345,925	-20,864 Reduced 11.73%	156,944 $2.44 Million
Q1 2021 May 13, 2021	SELL	$14.0 - $20.72 $286,076 - $423,392	-20,434 Reduced 10.31%	177,808 $2.55 Million
Q4 2020 Feb 09, 2021	BUY	$12.67 - $26.23 $264,169 - $546,895	20,850 Added 11.75%	198,242 $3.89 Million
Q3 2020 Nov 05, 2020	SELL	$11.92 - $15.87 $9,023 - $12,013	-757 Reduced 0.42%	177,392 $2.3 Million
Q2 2020 Aug 13, 2020	BUY	$7.53 - $14.93 $932,492 - $1.85 Million	123,837 Added 228.01%	178,149 $2.6 Million
Q1 2020 May 14, 2020	BUY	$5.69 - $17.78 $309,035 - $965,667	54,312 New	54,312 $462,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

85M

Call Options Held

18.4K

Put Options Held

51.3K

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Atara Biotherapeutics, Inc. Transaction History